Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. VTYX
stocks logo

VTYX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.364
-11.15%
--
--
-0.365
-6.41%
--
--
-0.383
+0.88%
Estimates Revision
The market is revising No Change the revenue expectations for Ventyx Biosciences, Inc. (VTYX) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 217.46%.
Revenue Estimates for FY2026
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-14.9%
In Past 3 Month
Stock Price
Go Up
up Image
+217.46%
In Past 3 Month
Wall Street analysts forecast VTYX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTYX is 13.67 USD with a low forecast of 2.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast VTYX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTYX is 13.67 USD with a low forecast of 2.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 8.000
sliders
Low
2.00
Averages
13.67
High
21.00
Current: 8.000
sliders
Low
2.00
Averages
13.67
High
21.00
Canaccord
Buy
maintain
$14 -> $16
2025-11-07
Reason
Canaccord
Price Target
$14 -> $16
2025-11-07
maintain
Buy
Reason
Canaccord raised the firm's price target on Ventyx Biosciences to $16 from $14 and keeps a Buy rating on the shares. The firm said the target increase is associated with reduced near-term OpEx projections based on the company's latest financial results as well as the clinical development status with less clinical trials currently ongoing, compared to 1Q and 2Q25.
H.C. Wainwright
H.C. Wainwright
Neutral -> Buy
upgrade
$18
2025-11-05
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$18
2025-11-05
upgrade
Neutral -> Buy
Reason
H.C. Wainwright upgraded Ventyx Biosciences to Buy from Neutral with an $18 price target. The firm says the recent acquisition from Novartis of Tourmaline highlights hsCRP biomarker for cardiovascular disease. Recent data from Ventyx's VTX3232 Phase 2 trial for obesity and cardiovascular risk factors "largely mimics" data presented from IL-6 inhibitor pacibekitug from Tourmaline which was acquired recently by Novartis for $1.4B in September, the analyst tells investors in a research note.
Oppenheimer
Oppenheimer
Outperform
maintain
$9 -> $14
2025-10-27
Reason
Oppenheimer
Oppenheimer
Price Target
$9 -> $14
2025-10-27
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Ventyx Biosciences to $14 from $9 and keeps an Outperform rating on the shares. The firm notes Ventyx announced Phase 2 data for CNS penetrant VTX3232 that changed up the story significantly. The data highlighted rapid reductions in hsCRP and other inflammatory biomarkers in this population of obese patients with cardiovascular risk factors. While these results closed the chapter on NLRP3 inhibitors in obesity, they threw open the door to addressing a validated biomarker for cardiovascular risk in hsCRP, Oppenheimer argues.
Clear Street
initiated
$11
2025-09-30
Reason
Clear Street
Price Target
$11
2025-09-30
initiated
Reason
Clear Street initiated coverage of Ventyx Biosciences (VTYX) with a Buy rating and $11 price target. The firm notes the stock has two seminal NLRP3 inhibitors' catalysts that are poised to drive valuation and partnership upside, the analyst tells investors in a research note. The forthcoming Q4 data for VTX2735 may advance it to pivotal recurrent pericarditis trials, supported by $209.0M cash and runway into the second half of 2026, and simultaneously, VTX3232's Q4 data in obesity-related cardiometabolic diseases will open Sanofi's (SNY) right-of-first-negotiation window, echoing its August 2025 Vigil acquisition, the firm added.
HC Wainwright & Co.
Emily Bodnar
Hold
Reiterates
n/a
2025-01-14
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
n/a
2025-01-14
Reiterates
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Ventyx Biosciences Inc (VTYX.O) is -5.14, compared to its 5-year average forward P/E of -5.55. For a more detailed relative valuation and DCF analysis to assess Ventyx Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.55
Current PE
-5.14
Overvalued PE
-1.03
Undervalued PE
-10.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.48
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.21
Undervalued EV/EBITDA
-8.17

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 427.27% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

VTYX News & Events

Events Timeline

(ET)
2025-12-02
07:10:00
VTX2735 Receives Approval for Phase 2 Trial in Recurrent Pericarditis Patients
select
2025-12-02
07:10:00
Ventyx Biosciences Adds Two Experts to Advisory Board Amid Phase 2 Study Update
select
2025-11-06 (ET)
2025-11-06
16:42:55
Ventyx Biosciences Announces Q3 Earnings Per Share of 32 Cents, Below Consensus Estimate of 45 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
12-02Globenewswire
Ventyx Biosciences Expands Phase 2 Study and Adds Strategic Advisors
  • Advisory Team Expansion: Ventyx Biosciences has appointed Mark McKenna and Peter Libby as strategic and clinical advisors, leveraging their expertise in immunology and cardiovascular fields to enhance decision-making capabilities in the development of NLRP3 inhibitors.
  • Clinical Trial Expansion: The company is expanding its Phase 2 study of VTX2735 into Canada, the EU, and the UK, aiming to accelerate Phase 3 development timelines by introducing a new once-daily dosing regimen, which is expected to significantly enhance its competitive position in the global market.
  • Data Release Adjustment: Ventyx has revised the topline data release for the Phase 2 study to Q1 2026; while this represents a modest delay, it provides an opportunity to introduce the new dosing regimen, thereby optimizing the overall efficiency of the clinical trial process.
  • R&D Day Event: The company plans to host an R&D Day in Q1 2026, where it will present interim data from the Phase 2 study and pharmacokinetic characteristics of the new dosing regimen, further boosting investor confidence in the company's research progress.
[object Object]
Preview
3.5
12-02Newsfilter
Ventyx Biosciences Expands Advisory Board and Clinical Study in Multiple Regions
  • Advisory Board Expansion: Ventyx Biosciences has appointed Mark McKenna and Peter Libby as strategic and clinical advisors, enhancing the company's expertise in inflammation-related diseases, which is expected to improve the quality and efficiency of its R&D decisions.
  • Clinical Study Expansion: The company is expanding its Phase 2 recurrent pericarditis study into Canada, the EU, and the UK, planning to accelerate global Phase 3 development by introducing a new once-daily dosing regimen, which could significantly enhance its market competitiveness.
  • Data Release Adjustment: Ventyx has revised the topline data release timeline for its Phase 2 study to Q1 2026; while this represents a modest delay, it allows for the introduction of dose-ranging studies that may enhance the trial's effectiveness.
  • R&D Day Event: The company plans to host an R&D Day in Q1 2026, where it will present interim Phase 2 data and pharmacokinetic characteristics of the new formulation, aiming to attract investor interest and enhance market awareness.
[object Object]
Preview
4.0
12-02Benzinga
Analyst Recognizes Potential in Neumora's Growing Obesity and Metabolic Portfolio

  • RBC Capital Markets Upgrade: Neumora Therapeutics, Inc. has been upgraded from Sector Perform to Outperform by RBC Capital Markets, with a price target increase from $4 to $7, reflecting the company's potential beyond neurology.

  • Pipeline Developments: Neumora is advancing its NMRA-215 obesity treatment, showing promising preclinical results, and plans to initiate a clinical program in early 2026, alongside ongoing studies for its M4 franchise targeting neuropsychiatric disorders.

  • Financial Outlook: The company has $171.5 million in cash and equivalents, which is expected to sustain operations through 2027, indicating a solid financial position for upcoming developments.

  • Market Potential: Analysts highlight the NLRP3 target as a significant opportunity in metabolic and obesity treatments, with Neumora positioned to capitalize on this emerging market, despite some caution regarding its later-stage neuro programs.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Ventyx Biosciences Inc (VTYX) stock price today?

The current price of VTYX is 8 USD — it has increased 2.04 % in the last trading day.

arrow icon

What is Ventyx Biosciences Inc (VTYX)'s business?

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its lead portfolio of NOD-like receptor protein 3 (NLRP3) inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase II development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase II development for neurodegenerative and cardiometabolic diseases. Its inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase II clinical trials. Tamuzimod is a sphingosine 1 phosphate receptor (S1P1R) modulator in development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is a selective allosteric tyrosine kinase type 2 (TYK2) inhibitor in Phase II development for the treatment of moderately to severely active Crohn’s disease.

arrow icon

What is the price predicton of VTYX Stock?

Wall Street analysts forecast VTYX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTYX is 13.67 USD with a low forecast of 2.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Ventyx Biosciences Inc (VTYX)'s revenue for the last quarter?

Ventyx Biosciences Inc revenue for the last quarter amounts to -24.87M USD, decreased -35.48 % YoY.

arrow icon

What is Ventyx Biosciences Inc (VTYX)'s earnings per share (EPS) for the last quarter?

Ventyx Biosciences Inc. EPS for the last quarter amounts to -17558000.00 USD, decreased -50.49 % YoY.

arrow icon

What changes have occurred in the market's expectations for Ventyx Biosciences Inc (VTYX)'s fundamentals?

The market is revising No Change the revenue expectations for Ventyx Biosciences, Inc. (VTYX) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 217.46%.
arrow icon

How many employees does Ventyx Biosciences Inc (VTYX). have?

Ventyx Biosciences Inc (VTYX) has 79 emplpoyees as of December 05 2025.

arrow icon

What is Ventyx Biosciences Inc (VTYX) market cap?

Today VTYX has the market capitalization of 570.87M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free